164 related articles for article (PubMed ID: 16493461)
1. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.
García MD; Wilson AJ; Emmerson DP; Jenkins PR; Mahale S; Chaudhuri B
Org Biomol Chem; 2006 Dec; 4(24):4478-84. PubMed ID: 17268643
[TBL] [Abstract][Full Text] [Related]
3. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
[TBL] [Abstract][Full Text] [Related]
5. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
Aubry C; Wilson AJ; Emmerson D; Murphy E; Chan YY; Dickens MP; García MD; Jenkins PR; Mahale S; Chaudhuri B
Bioorg Med Chem; 2009 Aug; 17(16):6073-84. PubMed ID: 19632122
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4.
Jenkins PR; Wilson J; Emmerson D; Garcia MD; Smith MR; Gray SJ; Britton RG; Mahale S; Chaudhuri B
Bioorg Med Chem; 2008 Aug; 16(16):7728-39. PubMed ID: 18650093
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
9. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.
Mahale S; Aubry C; James Wilson A; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Med Chem Lett; 2006 Aug; 16(16):4272-8. PubMed ID: 16750360
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
12. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
13. New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation.
Tu S; Zhang J; Zhu X; Xu J; Zhang Y; Wang Q; Jia R; Jiang B; Zhang J
Bioorg Med Chem Lett; 2006 Jul; 16(13):3578-81. PubMed ID: 16621547
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
15. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design.
Jantschko W; Furtmüller PG; Zederbauer M; Neugschwandtner K; Lehner I; Jakopitsch C; Arnhold J; Obinger C
Biochem Pharmacol; 2005 Apr; 69(8):1149-57. PubMed ID: 15794935
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
[TBL] [Abstract][Full Text] [Related]
17. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
[TBL] [Abstract][Full Text] [Related]
18. Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
Shafiq MI; Steinbrecher T; Schmid R
PLoS One; 2012; 7(8):e42612. PubMed ID: 22905154
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
Ashton KS; St Jean DJ; Poon SF; Lee MR; Allen JG; Zhang S; Lofgren JA; Zhang X; Fotsch C; Hungate R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5191-6. PubMed ID: 21824779
[TBL] [Abstract][Full Text] [Related]
20. New scoring functions for virtual screening from molecular dynamics simulations with a quantum-refined force-field (QRFF-MD). Application to cyclin-dependent kinase 2.
Ferrara P; Curioni A; Vangrevelinghe E; Meyer T; Mordasini T; Andreoni W; Acklin P; Jacoby E
J Chem Inf Model; 2006; 46(1):254-63. PubMed ID: 16426061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]